With Diminishing Cash, Aryx Seeks Pharma Partners For Mid-Stage Assets
This article was originally published in The Pink Sheet Daily
Executive Summary
Management expects clarity from FDA on the clinical development program for two drugs that will help finalize a deal.
You may also be interested in...
FDA Calls For Pre-Market CV Safety Trials For Some Constipation Drugs
Serotonin receptor 4 agonists for use in constipation have been in limbo due to potential for CV risk; FDA is seeking recommendations about safety studies for the class from an advisory committee.
FDA Calls For Pre-Market CV Safety Trials For Some Constipation Drugs
Serotonin receptor 4 agonists for use in constipation have been in limbo due to potential for CV risk; FDA is seeking recommendations about safety studies for the class from an advisory committee.
People In The News: Tracking The Latest Industry Personnel Moves
Presidents and CEOs